Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
NovoCure Ltd
Report date March 04, 2026 · Filed March 05, 2026
Section 16 reporting ended · disclosed 2026-03-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 422,570 |
Reported balance
After 2026-03-04 transaction · row 1
1 source rowRow 1 · 2026-03-04 · Tax withholding · Disposed 17,638 · Balance 422,570 F1: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 5, 2026 21:33 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 17,638 | $13.30 | $234,585.40 |
DisclosureSEC source: 0001822014-26-000003 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Former Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,570 F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 7,228 | $13.67 | $98,806.76 |
DisclosureSEC source: 0001822014-26-000002 · primarydocument.xml · nonDerivative · entry 4 Cordova Ashley · CIK 0001822014 · Former Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,208 F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 2,410 | $13.67 | $32,944.70 |
DisclosureSEC source: 0001822014-26-000002 · primarydocument.xml · nonDerivative · entry 3 Cordova Ashley · CIK 0001822014 · Former Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 447,436 F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). Read SEC document |
| February 28, 2026 Filed Mar 3, 2026 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 23,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001822014-26-000002 · primarydocument.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Former Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 449,846 F2 · security: Represents vesting of performance-based restricted stock units. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:09 UTC | NovoCure Ltd NVCR · Entity 4494 | Tax withholdingOrdinary Shares | 11,541 | $13.75 | $158,688.75 |
DisclosureSEC source: 0001822014-26-000002 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Former Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 426,028 F1 · shares: Represents the number of shares required to be withheld by the issuer to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This transaction is not discretionary and approved as required pursuant to Rules 16b-3(e) and 16b-3(d)(1). Read SEC document |
| September 05, 2025 Filed Sep 8, 2025 11:10 UTC | NovoCure Ltd NVCR · Entity 4494 | PurchaseOrdinary Shares | 81,550 | $12.22 | $996,859.05 |
DisclosureSEC source: 0001562180-25-006130 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437,569 F1 · price: On the transaction date, the reporting person purchased 81,550 shares in multiple trades at prices ranging from $12.02 to $12.47. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide to the Staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 30, 2025 Filed Jul 1, 2025 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 833 | $15.13 | $12,603.29 |
DisclosureSEC source: 0001562180-25-005186 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 356,019 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the 2025 NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2025 through June 30, 2025. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2025. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:39 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 224,123 | $18.19 Strike: $18.19 | $4,076,797.37 |
DisclosureSEC source: 0001562180-25-002156 · primarydocument.xml · derivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,123 Underlying: Ordinary Shares · 224,123 shares Expires 2035-03-03 F2 · derivative.exercise_date: Options to buy 224,123 ordinary shares will vest in equal installments on each of March 4, 2026, 2027, 2028 and 2029, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:39 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 151,181 | $18.19 | $2,749,982.39 |
DisclosureSEC source: 0001562180-25-002156 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,186 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 4, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:19 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,053 | $18.54 | $38,055.02 |
DisclosureSEC source: 0001562180-25-001975 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,005 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: On the transaction date, the reporting person sold 2,053 shares in multiple trades at prices ranging from $18.02 to $18.9918. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 02:26 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,341 | $18.28 | $42,803.55 |
DisclosureSEC source: 0001562180-25-001916 · primarydocument.xml · nonDerivative · entry 3 Cordova Ashley · CIK 0001822014 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,058 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: On February 28, 2025, the reporting person sold 2,341 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 28, 2025 Filed Mar 3, 2025 21:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,341 | $18.28 | $42,803.55 |
DisclosureSEC source: 0001562180-25-001833 · primarydocument.xml · nonDerivative · entry 3 Cordova Ashley · CIK 0001822014 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 206,058 F3 · price: On February 28, 2025, the reporting person sold 2,341 shares in multiple trades at prices ranging from $18.175 to $18.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:26 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,808 | $20.55 | $37,152.59 |
DisclosureSEC source: 0001562180-25-001916 · primarydocument.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,399 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F3 · price: On February 27, 2025, the reporting person sold 1,808 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 02:26 UTC Amendment | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 9,345 | $19.92 | $186,170.16 |
DisclosureSEC source: 0001562180-25-001916 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,207 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: On February 27, 2025, the reporting person sold 9,345 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,808 | $20.55 | $37,152.59 |
DisclosureSEC source: 0001562180-25-001833 · primarydocument.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,399 F2 · price: On February 27, 2025, the reporting person sold 1,808 shares in multiple trades at prices ranging from $20.41 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 9,345 | $19.92 | $186,170.16 |
DisclosureSEC source: 0001562180-25-001833 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,207 F1 · price: On February 27, 2025, the reporting person sold 9,345 shares in multiple trades at prices ranging from $19.41 to $20.4033. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:04 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 373 | $14.75 | $5,501.00 |
DisclosureSEC source: 0001562180-25-000066 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,552 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2024 through December 31, 2024. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2024. Read SEC document |
| August 02, 2024 Filed Aug 5, 2024 20:25 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 688 | $20.14 | $13,857.42 |
DisclosureSEC source: 0001562180-24-005984 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,179 F1 · price: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 28, 2024 Filed Aug 6, 2024 20:19 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 1,286 | $12.24 | $15,740.64 |
DisclosureSEC source: 0001562180-24-006040 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,465 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 28, 2024. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:43 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantStock Options (Right to buy) · Derivative | 156,348 | $16.30 Strike: $16.30 | $2,548,472.40 |
DisclosureSEC source: 0001562180-24-001989 · primarydocument.xml · derivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,348 Underlying: Ordinary Shares · 156,348 shares Expires 2034-02-26 F2 · derivative.exercise_date: Options to buy 156,348 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:43 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 102,249 | $16.30 | $1,666,658.70 |
DisclosureSEC source: 0001562180-24-001989 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,867 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| November 02, 2023 Filed Nov 2, 2023 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionStock Option (Right to Buy) · Derivative | 175 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001562180-23-007502 · primarydocument.xml · derivative · entry 8 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 175 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Vests 2,686 share(s) on 24-Feb-2019, 6,250 share(s) on 24-Feb-2020 Read SEC document |
| November 02, 2023 Filed Nov 2, 2023 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 175 | $11.46 | $2,005.50 |
DisclosureSEC source: 0001562180-23-007502 · primarydocument.xml · nonDerivative · entry 4 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,618 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,752 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001562180-23-007502 · primarydocument.xml · derivative · entry 7 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,752 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Vests 2 share(s) on 22-Feb-2018, 9,750 share(s) on 22-Feb-2021 Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,480 | $0.00 Strike: $11.44 | $0.00 |
DisclosureSEC source: 0001562180-23-007502 · primarydocument.xml · derivative · entry 6 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 2,480 shares Expires 2026-07-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,561 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001562180-23-007502 · primarydocument.xml · derivative · entry 5 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175 Underlying: Ordinary Shares · 7,561 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Vests 2,686 share(s) on 24-Feb-2019, 6,250 share(s) on 24-Feb-2020 Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,752 | $7.15 | $55,426.80 |
DisclosureSEC source: 0001562180-23-007502 · primarydocument.xml · nonDerivative · entry 3 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 2,480 | $11.44 | $28,371.20 |
DisclosureSEC source: 0001562180-23-007502 · primarydocument.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 20:20 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,561 | $11.46 | $86,649.06 |
DisclosureSEC source: 0001562180-23-007502 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 01, 2023 Filed Sep 5, 2023 20:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 883 | $21.82 | $19,264.59 |
DisclosureSEC source: 0001562180-23-006686 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,650 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| August 02, 2023 Filed Aug 4, 2023 20:02 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,144 | $30.25 | $34,607.26 |
DisclosureSEC source: 0001562180-23-006182 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,533 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 367 | $35.28 | $12,947.76 |
DisclosureSEC source: 0001562180-23-005757 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,677 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:40 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 11,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002490 · primarydocument.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,815 F2 · shares: Represents vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:51 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 775 | $76.16 | $59,023.54 |
DisclosureSEC source: 0001562180-23-002578 · primarydocument.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,310 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:51 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,730 | $76.16 | $360,233.96 |
DisclosureSEC source: 0001562180-23-002578 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,085 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:40 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,055 | $75.28 | $79,418.18 |
DisclosureSEC source: 0001562180-23-002490 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,007 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:55 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,198 | $76.36 | $167,844.56 |
DisclosureSEC source: 0001645113-23-000027 · wf-form4_167779410749716.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,062 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:55 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 39,614 | $76.97 Strike: $76.97 | $3,049,089.58 |
DisclosureSEC source: 0001645113-23-000027 · wf-form4_167779410749716.xml · derivative · entry 3 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,614 Underlying: Ordinary Shares · 39,614 shares Expires 2033-02-27 F3 · derivative.exercise_date: Options to buy 39,614 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:55 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 23,818 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-23-000027 · wf-form4_167779410749716.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,260 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 21:18 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 66 | $62.31 | $4,112.13 |
DisclosureSEC source: 0001645113-23-000014 · wf-form4_167338547170322.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,442 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 21:33 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 2,000 | $7.15 Strike: $7.15 | $14,300.00 |
DisclosureSEC source: 0001645113-22-000096 · wf-form4_167027597587120.xml · derivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,752 Underlying: Ordinary Shares · 2,000 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 21:33 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 2,000 | $7.15 | $14,300.00 |
DisclosureSEC source: 0001645113-22-000096 · wf-form4_167027597587120.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,376 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 21:15 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 885 | $79.04 | $69,947.75 |
DisclosureSEC source: 0001645113-22-000077 · wf-form4_166249891435026.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,376 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| August 02, 2022 Filed Aug 3, 2022 20:45 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 7,122 | $70.20 | $499,964.40 |
DisclosureSEC source: 0001645113-22-000072 · wf-form4_165955948883661.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,261 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of August 2, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| July 05, 2022 Filed Jul 7, 2022 21:49 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 251 | $59.08 | $14,827.83 |
DisclosureSEC source: 0001645113-22-000064 · wf-form4_165723055863070.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,139 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2022. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 21:51 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 759 | $70.10 | $53,205.90 |
DisclosureSEC source: 0001645113-22-000026 · wf-form4_164686266443195.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,848 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F1 · balance_after: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 04, 2022 Filed Mar 7, 2022 23:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 556 | $70.41 | $39,146.29 |
DisclosureSEC source: 0001645113-22-000022 · wf-form4_164669559462387.xml · nonDerivative · entry 3 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,607 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:26 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 5,140 | $80.59 Strike: $80.59 | $414,232.60 |
DisclosureSEC source: 0001645113-22-000022 · wf-form4_164669559462387.xml · derivative · entry 5 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,140 Underlying: Ordinary Shares · 5,140 shares Expires 2032-02-29 F4 · shares: Options to buy 5,140 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:26 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 37,664 | $80.59 Strike: $80.59 | $3,035,341.76 |
DisclosureSEC source: 0001645113-22-000022 · wf-form4_164669559462387.xml · derivative · entry 4 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,664 Underlying: Ordinary Shares · 37,664 shares Expires 2032-02-29 F3 · shares: Options to buy 37,664 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:26 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,149 | $74.50 | $85,598.20 |
DisclosureSEC source: 0001645113-22-000022 · wf-form4_164669559462387.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,163 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.